Natco Pharma Ltd
NSE:NATCOPHARM
Natco Pharma Ltd
Income from Continuing Operations
Natco Pharma Ltd
Income from Continuing Operations Peer Comparison
Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors
Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Natco Pharma Ltd
NSE:NATCOPHARM
|
Income from Continuing Operations
₹12.8B
|
CAGR 3-Years
38%
|
CAGR 5-Years
9%
|
CAGR 10-Years
32%
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Income from Continuing Operations
₹55.8B
|
CAGR 3-Years
43%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
Cipla Ltd
NSE:CIPLA
|
Income from Continuing Operations
₹41.6B
|
CAGR 3-Years
20%
|
CAGR 5-Years
22%
|
CAGR 10-Years
11%
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Income from Continuing Operations
₹90B
|
CAGR 3-Years
67%
|
CAGR 5-Years
19%
|
CAGR 10-Years
11%
|
|
Zydus Lifesciences Ltd
NSE:ZYDUSLIFE
|
Income from Continuing Operations
₹38.3B
|
CAGR 3-Years
20%
|
CAGR 5-Years
16%
|
CAGR 10-Years
16%
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Income from Continuing Operations
₹15B
|
CAGR 3-Years
8%
|
CAGR 5-Years
13%
|
CAGR 10-Years
11%
|
See Also
What is Natco Pharma Ltd's Income from Continuing Operations?
Income from Continuing Operations
12.8B
INR
Based on the financial report for Dec 31, 2023, Natco Pharma Ltd's Income from Continuing Operations amounts to 12.8B INR.
What is Natco Pharma Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
32%
Over the last year, the Income from Continuing Operations growth was 228%. The average annual Income from Continuing Operations growth rates for Natco Pharma Ltd have been 38% over the past three years , 9% over the past five years , and 32% over the past ten years .